Chiasma licenses acromegaly drug candidate Octreolin to Roche

02/19/2013 | PharmaTimes (U.K.) · Fox Business

Chiasma granted Roche Holding exclusive worldwide rights to develop and market its experimental growth hormone disorder drug Octreolin, an oral form of the somatostatin analogue ocreotide, first as a treatment for acromegaly and later for neuroendocrine tumors. Roche unit Genentech will sell the product in the U.S. if it is approved by the FDA. Chiasma will get $65 million upfront and as much as $530 million in milestones payments plus sales royalties.

View Full Article in:

PharmaTimes (U.K.) · Fox Business

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL